Equities research analysts at StockNews.com assumed coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS – Get Rating) in a report issued on Thursday. The firm set a "sell" rating on the stock.

Ayala Pharmaceuticals Stock Performance

Shares of ADXS traded up $0.14 on Thursday, reaching $1.50. The stock had a trading volume of 3,325 shares, compared to its average volume of 7,793. Ayala Pharmaceuticals has a 12-month low of $1.00 and a 12-month high of $10.71.

About Ayala Pharmaceuticals

(Get Rating)

Advaxis, Inc is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy.

See Also

• Get a free copy of the StockNews.com research report on Ayala Pharmaceuticals (ADXS)
• KB Home Strong Results Lift Prices
• Chewy Stock Is Setting Up For Long-Term Profitable Growth
• Why Wall Street Loves These 3 Penny Stocks
• Carvana May Be Able To Reach Profitability This Year
• Low Volume Bunge Plunge Presents an Opportunity

Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.